METHODS FOR TREATING OR PREVENTING CONTACT-ACTIVATION PATHWAY-ASSOCIATED DISEASES USING iRNA COMPOSITIONS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12)
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsJames Butler, Jingxuan Liu
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of use of RNAi agents, e.g., double stranded RNAi agents, targeting a Factor XII (Hageman Factor (F12) gene, for treating subjects having a contact activation pathway-associated disease, such as a thrombophilia or hereditary angioedema (HAE), methods for preventing at least one symptom in a subject having a contact activation pathway-associated disease, such as a thrombus formation or an angioedema attack, and RNAi agents targeting an F12 gene, for use in the methods of the invention.
Claims25
A double stranded ribonucleic acid (dsRNA) agent that inhibits the expression of F12 for use in treating a subject having a contact activation pathway-associated disease,
- wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the antisense strand comprises at least 15 contiguous nucleotides differing b no more than 3 nucleotides from the nucleotide sequence of
- 5'-UUCAAAGCACUUUAUUGAGUUUC-3' (SEQ ID NO:899),
- wherein when the dsRNA agent is administered to the subject, hemostasis in the subject is not inhibited.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.